The international operation of Chinese pharmaceutical company, HUYA Bioscience International (HUYA) has expanded its Senior Management Team, with the appointment of Yoshiki Shimamura as Vice President for Japan Operations.

Mr. Shimamura has more than 25 years of experience in the biopharma industry and clinical research organizations in Japan and South Korea, including companies such as Novocure KK, Hospira Japan Co Ltd, Chong Kun Dang Pharmaceutical Co, Amgen and Taiho Pharmaceutical Co Ltd.

"It is a pleasure to welcome Yoshiki Shimamura to the HUYA team as we expand our activities in Japan," said Mireille Gillings, CEO of HUYA. "His broad experience in clinical operations, business development and marketing will help HUYA advance candidate products in the Japanese market. Here, we are making unprecedented use of the Tripartite Health Cooperation between China, Korea and Japan. Our aim is to accelerate approval of our products in Japan based on Chinese clinical trials data."

Educated in Japan, Mr. Shimamura has a B.Sc. in Molecular and Cell Biology from Saitama University, and an M.Sc. in Pharmaceutical Science from Chiba University. He has been a postgraduate researcher in Disease Biochemistry at Tokyo University of Pharmaceutical and Life Sciences, and he is currently a postgraduate researcher in Life Science Technology at Tokushima University, and aims to complete his PhD in March 2016.